**Supplementary Table S1.** Clinico-pathological characteristics of the cohort of 96 triple-negative breast cancer (TNBC) patients by type of response to neoadjuvant chemotherapy (NAC).

| _   | Partial responders<br>(n=63) | Non-responders<br>(n=33) | р                   |
|---|------------------------------|--------------------------|---------------------|
|   |                              |                          |                     |
| Age Years, median (IQR)                     | 51.00 (25.00)                | 55.00 (25.00)            | 0.452*              |
| Menopausal status                           |                              |                          |                     |
| Pre-menopausal                              | 24 (47.1%)                   | 11 (40.7%)               | 0.768 <sup>†</sup>  |
| Menopausal                                  | 27 (52.9%)                   | 16 (59.3%)               |                     |
| Histological grade                          |                              |                          |                     |
| < 3   | 10 (16.7%)                   | 7 (21.9%)                | 0.741 <sup>+</sup>  |
| 3   | 50 (83.3%)                   | 25 (78.1%)               |                     |
| Tumour diameter                             |                              |                          |                     |
| mm, median (IQR)                            | 22.00 (21.00)                | 30.00 (35.00)            | 0.003*              |
| Nodal status                                |                              |                          |                     |
| Negative                                    | 37 (60.7%)                   | 4 (12.1%)                | <0.001 <sup>+</sup> |
| Positive                                    | 24 (39.3%)                   | 29 (87.9%)               |                     |
| Ki67 degree                                 |                              |                          |                     |
| ≤ 30%                                       | 14 (25.9%)                   | 10 (31.3%)               | 0.777 <sup>†</sup>  |
| > 30%                                       | 40 (74.1%)                   | 22 (68.8%)               |                     |
| Surgery                                     |                              |                          |                     |
| Tumorectomy                                 | 26 (42.6%)                   | 10 (30.3%)               | 0.342 <sup>+</sup>  |
| Mastectomy                                  | 35 (57.4%)                   | 23 (69.7%)               |                     |
| No lymphadenectomy                          | 17 (27.9%)                   | 3 (9.1%)                 | 0.063 <sup>+</sup>  |
| Lymphadenectomy                             | 44 (72.1%)                   | 30 (90.9%)               |                     |
| Adjuvant treatment                          |                              |                          |                     |
| No  | 51 (83.6%)                   | 26 (81.3%)               | 1.000 <sup>†</sup>  |
| Yes   | 10 (16.4%)                   | 6 (18.8%)                |                     |
| Radiotherapy                                |                              |                          |                     |
| No  | 4 (4.6%)                     | 0 (0.0%)                 | 0.295 <sup>†</sup>  |
| Yes   | 54 (93.1%)                   | 30 (100.0%)              |                     |
| Relapse                                     |                              |                          |                     |
| No  | 40 (63.5%)                   | 14 (43.8%)               | 0.106 <sup>†</sup>  |
| Yes   | 23 (36.5%)                   | 18 (56.3%)               |                     |
| Overall survival (median months             | EO 80 (24 02)                | 20 27 /26 17\            | 0.036*              |
| (IQR))                                      | 59.80 (34.93)                | 38.37 (36.17)            | 0.026*              |
| Relapse-free survival (median months (IQR)) | 45.47 (45.80)                | 29.53 (40.13)            | 0.056*              |
| Status                                      |                              |                          |                     |
| Alive                                       | 42 (66.7%)                   | 17 (51.5%)               | 0.219 <sup>†</sup>  |
| Dead  | 21 (33.3%)                   | 16 (48.5%)               |                     |

Data are presented as the median and interquartile range (Mann–Whitney U test, \*), and the number and percentage of patients in each category (chi-squared test, ¹). Age, menopausal status, histological grade, tumour diameter, nodal status, and Ki67 degree were recorded at the time of diagnosis. Overall survival and relapse-free survival were censored at 60 months.